Trafalgar International (GCAN) EBIT Growth (3y) (2020 - 2026)
Trafalgar International (GCAN) EBIT Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 29.31% |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 4.24% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 0.90% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 1.82% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -74.25% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 27.21% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 35.42% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.44% |
| Dec 31, 2025 | -8.38% |
| Sep 30, 2025 | 8.79% |
| Jun 30, 2025 | -3.89% |
| Mar 31, 2025 | -0.86% |
| Dec 31, 2024 | 32.08% |
| Sep 30, 2024 | 18.36% |
| Jun 30, 2024 | 14.35% |
| Mar 31, 2024 | 23.27% |
| Dec 31, 2023 | 6.31% |
| Sep 30, 2023 | 10.72% |
| Jun 30, 2023 | 20.34% |
| Mar 31, 2023 | 23.48% |
| Dec 31, 2022 | 39.90% |
| Sep 30, 2022 | 14.34% |
| Jun 30, 2022 | 35.86% |
| Mar 31, 2022 | 21.90% |
| Dec 31, 2021 | -16.39% |
| Sep 30, 2021 | 28.18% |
| Jun 30, 2021 | -68.68% |